A Rare Case of Soft Tissue Erdheim Chester Disease: Diagnostic Dilemma and Management
DOI:
https://doi.org/10.3889/oamjms.2019.231Keywords:
Histiocytosis, Diagnosis, BRAF mutation, Interferon, Erdheim Chester DiseaseAbstract
BACKGROUND: Erdheim Chester disease (ECD) is a rare form of non-Langerhans histiocytosis that still presents a diagnostic and clinical dilemma.
CASE PRESENTATION: We present a rare case of ECD, young 31 male with atypical localisation and soft tissue presentation and no bone involvement. He started clinical investigations due to subcutaneous tumour mass in the lumbar spine that caused severe back pain. Skin biopsy revealed ECD with Immunohistochemistry CD68+, CD10+, CD11c+, vimentin+, S100A4+. Activating BRAFV600E mutation was positive from the tumour tissue. The patient was referred to the haematology department. PET CT was performed for initial disease staging. Treatment was started with corticosteroids (methylprednisolone 0.5 mg/kg per day), and after 7 days, a significant clinical improvement was noticed in terms of pain disappearance with no need for pain killers. After two weeks, treatment with interferon Alfa (IFN-α) was started in a dose of 3 million units 3 times per week. After 4 months of interim treatment PET, CT revealed a significant reduction of the tumour mass. Therapy with IFN-α was continued, and the patient is still clinically in good condition.
CONCLUSION: It can be concluded that shortening the time of diagnosis of ECD is essential in treatment outcome of this disease. Still, large studies have to confirm the best treatment of this rare condition.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Chester W. Lipoidgranulomatose. Virchows Arch Pathol Anat. 1930; 279:561-602. https://doi.org/10.1007/BF01942684
Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in ErdheimChester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012; 120(13):2700-2703. https://doi.org/10.1182/blood-2012-05-430140 PMid:22879539
Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, Arnaud L, Haroche J. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014; 124(4):483-492. https://doi.org/10.1182/blood-2014-03-561381 PMid:24850756 PMCid:PMC4110656
Dion E, Graef C, Miquel A, Haroche J, Wechsler B, Amoura Z, Zeitoun D, Grenier PA, Piette JC, Laredo JD. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology. 2006; 238(2):632-9. https://doi.org/10.1148/radiol.2382041525 PMid:16371583
Wittenberg KH, Swensen SJ, Myers JL. Pulmonary involvement with Erdheim-Chester disease: radiographic and CT findings. AJR Am J Roentgenol. 2000; 174(5):1327-31. https://doi.org/10.2214/ajr.174.5.1741327 PMid:10789787
Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, MartÃnez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology- Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol. 2018; 4(3):384-388. https://doi.org/10.1001/jamaoncol.2017.5029 PMid:29188284 PMCid:PMC5844839
Young JR, Johnson GB, Murphy RC, Go RS, Broski SM. (18) F-FDG PET / CT in Erdheim - Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. J Nucl Med. 2018; 59(5):774-779. https://doi.org/10.2967/jnumed.117.200741 PMid:29097410
Fadi Braiteh, Cynthia Boxrud, Bita Esmaeli, Razelle Kurzrock. Successful treatment of Erdheim- Chester disease, a non - Langerhans - cell histiocytosis, with interferon - alfa. Blood. 2005; 106(9):2992-2994. https://doi.org/10.1182/blood-2005-06-2238 PMid:16020507
Adam Z, Petrášová H, Řehák Z, Koukalová R, KrejÄà M, Pour L, VeteÅ¡nÃková E, ÄŒermák A, Å evÄÃková S, Szturz P, Král Z, Mayer J. Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature. Vnitr Lek Fall. 2016; 62(10):820-832.
Cohen-Aubart F, Maksud P, Emile JF, Benameur N, Charlotte F, Cluzel P, Amoura Z, Haroche J. Efficacy of infliximab in the treatment of Erdheim-Chester disease. Ann Rheum Dis. 2018; 77(9):1387-1390. https://doi.org/10.1136/annrheumdis-2017-212678 PMid:29363511
Milne P, Bigley V, Bacon CM, Neel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017; 130(2):167-175. https://doi.org/10.1182/blood-2016-12-757823 PMid:28512190 PMCid:PMC5524529
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Aleksandra Pivkova-Veljanovska, Martin Ivanovski, Irina Panovska-Stavridis, Zlate Stojanoski, Sanja Trajkova, Angelika Karadzova-Stojanoska, Borche Georgievski, Slavica Kostadinova-Kunovska, Rubens Jovanovic, Gordana Petrushevska
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0